The Impact of the Epigenetic Cancer Drug Azacitidine on Host Immunity: The Role of Myelosuppression, Iron Overload...

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• The clinical efficacy of azacitidine, a hypomethylating agent, in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) is often limited by adverse events.
• Investigating host variables that influence azacitidine's real-world effectiveness is crucial for improving patient outcomes.

Purpose of the Study:

• To identify hematological adverse events and host variables that compromise azacitidine efficacy in MDS and AML.
• To elucidate the mechanisms underlying azacitidine-induced myelosuppression and increased infection susceptibility.

Main Methods:

• Utilized zebrafish models to study azacitidine's effects on myeloid precursors and function.
• Investigated the impact of iron overload and tp53 mutations on azacitidine treatment outcomes and bacterial infection susceptibility.
• Examined clinical data from MDS patients and azacitidine-treated individuals to assess the relevance of findings.

Main Results:

• Azacitidine treatment in zebrafish led to myeloid precursor destruction, impaired myeloid function, and increased susceptibility to bacterial infections.
• Iron overload exacerbated bacterial infections, particularly those with known iron dependence.
• tp53^M214K mutant zebrafish exhibited enhanced resistance to bacterial infections post-azacitidine treatment, attributed to hematopoietic cells.
• Clinical observations included severe azacitidine-induced bone marrow suppression and a correlation between hyperferritinemia and bacteremia in treated patients.

Conclusions:

• Myelosuppression, iron overload, and TP53 mutations are significant host variables that compromise azacitidine efficacy in MDS and AML.
• tp53^M214K-mediated resistance to myelosuppression may confer a survival advantage to malignant clones under azacitidine treatment.